New asthma inhaler faces off against standard treatment in major trial
NCT ID NCT07318350
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests a new inhaler called N0783 against a standard asthma inhaler (Alenia) in 174 adults with moderate asthma. The goal is to see if the new drug works just as well at improving lung function and controlling symptoms. Participants will be randomly assigned to one of the two inhalers and monitored for 12 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- N0783 (a fixed-dose combination inhaler)
- What this could lead to
- If it works, this could offer a new treatment option for people with moderate asthma that is as effective as current therapies.
- What could go wrong
- This is an early-stage Phase 3 trial with only 174 participants, so results may not apply to everyone. The new drug might not be as good as the standard treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.